Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial ...

The planned addition of the two 2000L single-use bioreactors in Q1 2026 will significantly enhance Bora Biologics' ability to provide seamless scale-up and commercial manufacturing solutions to ...